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We report the molecular characterization of seven
new keratinocyte transglutaminase mutations (R315C,
S358R, V379L, G473S, R687C, deletion D679–696,
R127Stop) found in lamellar ichthyosis patients. Arg-
315, Ser-358, Val-379, and Gly-473 are highly conserved
residues in transglutaminases while Arg-687 and D679–
696 are not. All mutations strongly decreased transglu-
taminase activity and protein levels. The mutation
R127Stop diminished the amount of mRNA. Structural
analysis of these mutations based on the factor XIII
A-subunit crystal structure demonstrated that Arg-315,
Ser-358, Val-379, and Gly-473 are located in the catalytic
core domain, and Arg-687 and the deletion are in the
b-barrel domains. The side chains of amino acids Arg-
315, Ser-358, and Gly-473 make ionic and hydrogen
bonds important for folding and structural stability of
the enzyme but are not directly involved in catalysis.
Val-379 is two amino acids away from the active site
cysteine, and its change into leucine disturbs the active
site structure. The decreased activity and protein level
after expression of the R687C and D679–696 TGK cDNA
in TGK negative keratinocytes excluded that they are
polymorphisms. These results identify important amino
acids in the central core domain of transglutaminases
and show that the C-terminal end influences the struc-
tural and functional integrity of TGK.
Transglutaminases (EC.2.3.2.13, protein-glutamine: amine
g-glutamyl-transferase) are a superfamily of enzymes which
catalyze the formation of intra- and intermolecular g-glutamyl-
e-lysine isodipeptide bonds (1, 2). They are calcium-dependent
enzymes that contain an active site consisting of a catalytic
triad (Cys, His, Asp) (3–5). The six different classes of trans-
glutaminases are participating in a wide variety of physiolog-
ical processes (3, 6, 7). One member of this family, keratinocyte
transglutaminase (TGK),1 is involved in cross-linkage during
formation of the cornified cell envelope (CE), a highly insoluble
8–15-nm wide structure replacing the plasma membrane in
terminal differentiating epidermis (8, 9). During this process,
CE precursor proteins such as loricrin, involucrin, and small
proline-rich proteins are sequentially cross-linked on the inner
side of the plasma membrane (10–13). TGK protein is localized
mainly to the cell periphery in the granular layer. The enzyme
consists of 815 amino acids, and it is post-translationally mod-
ified by fatty acid acylation and phosphorylation (14–17). Sev-
eral complexes consisting of the full-length protein and
polypeptides proteolytically cleaved from it have been identi-
fied in the cytosolic and membrane fractions (18, 19). Most of
the enzyme complexes are attached to the membrane through
myristate and palmitate chains (20, 21). About 5–10% of TGK
activity is found in the cytoplasmic fraction, which might be
involved in the final steps of CE assembly. Deletion analysis
showed that a molecule in which the first 109 and the last 240
amino acids have been removed retains a specific activity com-
parable with the full-length enzyme (22). The human TGK gene
consists of 15 exons and is located on chromosome 14q11 (23–
27). At least two different allelic variants have been detected in
the human population (24).
Autosomal recessive lamellar ichthyosis (LI) (Mendelian In-
heritance in Man No. 242100, 242300) is a severe congenital
scaling skin disorder with a frequency of about 1:250,000 (28,
29). The clinical phenotype is heterogeneous and can range
from generalized large brownish plate-like scales with no
erythroderma to fine white scales with underlying erythro-
derma. Moreover, patients may have palmar and plantar hy-
perkeratosis, scarring alopecia, ectropion, eclabium, and de-
creased sweating. Patients are often born encased in a shiny,
thick parchment-like membrane (collodion baby). By electron
microscopy, five types of lamellar ichthyosis (ichthyosis con-
genita type I-V) have been distinguished (30). Deleterious mu-
tations in the TGK gene have been reported in lamellar ichthy-
osis patients providing compelling evidence for the importance
of the cornified cell envelope for epidermal homeostasis and the
barrier function of the skin (31–33). However, biochemical data
clearly showed that about 50–60% of LI patients have normal
TG activity (34). Genetic heterogeneity is further supported by
genetic mapping studies identifying two other disease-causing
genes, one on chromosome 2q33–35 and another at a currently
unknown location (35).
We report seven novel TGK mutations found in LI patients.
The consequences of these mutations (five missense mutations,
one premature stop codon, and a deletion of 18 amino acids) on
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the biosynthesis of TGK mRNA and protein are described. The
effects of these mutations on folding and structure are analyzed
using the three-dimensional structure of factor XIII A-subunit
as model. This study identifies structurally and functionally
important amino acids of TGK and provides new insight into
the structure-function relationship in transglutaminases.
EXPERIMENTAL PROCEDURES
Patients—Families from Switzerland (LI-8), Holland (LI-11), Sweden
(LI-20), and the United States (LI-22) were investigated (see Fig. 1).
The proband of family LI-8 was born as a collodion baby and died
shortly after birth due to bacterial infection. The affected individual of
family LI-11 was not born as a collodion baby; his trunk and neck are
covered with large plate-like yellow-brown hyperkeratotic scales, and
he has very extensive palmar-plantar keratoderma with large fissures.
The face is not involved and there is no alopecia or ectropion. The
clinical data of the affected members of family LI-20 have been de-
scribed earlier (36). Patient IV.4 of LI-22 (see Fig. 1) was born as a
collodion baby after a normal, full-term pregnancy. He now has gener-
alized, thin white to brown scales that are more plate-like on the scalp
and the lower extremities. No blistering or significant erythroderma are
apparent. Palms and soles show moderate hyperkeratosis. Patient II.2
of LI-22 (Fig. 1) was not born as a collodion baby and now has thick
scales on the scalp, powdery fine scaling on the back and arms, and
hyperlinear palms. The affected members of family LI-22 had normal
cholesterol sulfate and cholesterol sulfatase levels.
Cell Culture—Punch biopsies obtained from the probands were used
to establish primary cultures on lethally irradiated murine 3T3 fibro-
blasts as described earlier (37–39). Secondary cultures were grown in
high calcium keratinocyte medium, 10% fetal calf serum until conflu-
ency. After an additional 5 days in culture, genomic DNA, RNA, and
proteins for measuring transglutaminase activity and immunoblotting
were extracted as described below.
Isolation of DNA and RNA—Genomic DNA was purified from cul-
tured cells by phenol/chloroform extraction as described earlier (40) or
from blood using NucleoSpin columns (Macherey-Nagel). Total RNA
was isolated using the guanidine-thiocyanate method (41).
Northern Blot Analysis—Denaturing RNA gels and transfer to Zeta-
probe membrane (Bio-Rad, Richmond, CA) were performed as described
earlier using 13 mg of total RNA/lane (42). Membranes were hybridized
with 32P-labeled TGK probes (DH42, 39 NC) and involucrin (33, 42).
Final washes were performed in 0.2 3 SSC, 0.1% SDS at 65 °C for
30 min.
Transglutaminase Assay—Cells were lysed by sonication in 20 mM
sodium phosphate, pH 7.2, 0.5 mM EDTA, 10 mM dithiothreitol, 50
mg/ml phenylmethylsulfonyl fluoride. The supernatant, after centrifu-
gation at 25,000 3 g at 4 °C for 30 min, was used as cytosolic fraction.
The cell pellet was re-extracted by sonication with the same buffer
supplemented with 1% Triton X-100. After incubation for 10 min at
37 °C, the lysate was centrifuged again, and the supernatant (mem-
brane fraction) was collected for measuring the transglutaminase ac-
tivity (43). Transglutaminase activity is expressed as pmol of 3H-pu-
trescine incorporated into dimethylcaseine per hour and per mg of
protein. Results are indicated as mean 6 S.E. in cell extracts from at
least two different cell passages, each measured in duplicate.
Western Blot Analysis—Cells were lysed by sonication in 10 mM
Tris-HCl, pH 7.4, 5 mM EDTA, 50 mg/ml phenylmethylsulfonyl fluoride,
1 mg/ml pepstatin, 1 mg/ml E-64, 1 mg/ml leupeptin. The supernatant,
after centrifugation at 25,000 3 g for 30 min, was taken as cytosolic
fraction. The membrane fraction was obtained after sonication of the
cell pellet in the same buffer supplemented with 1% Triton X-100 and
centrifugation. 40 mg of protein was size-fractionated by SDS-polyacryl-
amide gel electrophoresis through a 10% separation and 4% concentra-
tion gel (containing 4 M urea) and, after partial renaturation, electro-
blotted to nitrocellulose (9). TGK protein was visualized with antibody
B.C1 (8) and the ECL detection kit (Amersham, Switzerland).
Protein Concentrations—Protein content was determined with the
Bradford assay (Bio-Rad) using bovine serum albumin as standard (44).
DNA Sequencing and Family Analysis of Mutations—The 15 exons of
the TGK gene were amplified by PCR as described (33). Forward prim-
ers were biotinylated. PCR products were purified by QIAquick PCR
purification kit (Qiagen), and single-stranded DNA was isolated with
streptavidin-coated magnetic beads (Dynal) and sequenced with the
reverse primers using the Sequenase sequencing kit (Amersham). Nu-
cleotides have been numbered according to Phillips et al. (26). To
number amino acids, the first methionine of the open reading frame (15)
was designated as number 1. For inheritance analysis in families, DNA
was amplified by PCR, digested with restriction enzymes, and sepa-
rated on agarose or polyacrylamide gels.
Expression of Mutant Proteins—Full-length TGK cDNA was ob-
tained by RT-PCR using patients keratinocyte RNA and primers DH8
59-CATCCATCCTGACCTGTTCCA-39 (nt 279 to 259 (16)) and DH9
59-GTTTATTAGCATCTGTTCCCCCAGT-39 (nt 12580 to 12604 (16))
and cloned into the NotI site of pCI (Promega). The sequence was
verified by sequencing. b-Galactosidase cDNA was obtained from plas-
mid H3700-pL2 (45) and cloned into the NotI site of pCI. Plasmids were
purified over Qiagen columns and by Triton X-114 extraction (46).
Secondary keratinocytes from a TGK negative LI patient cultured on
irradiated 3T3 fibroblast feeder layer were transfected at 80–90% con-
fluency with 4 mg of the TGK-expressing plasmid and 2 mg of the
b-galactosidase expressing plasmid (47). Two days later, b-galactosid-
ase and transglutaminase activities were determined (43, 48).
Modeling of the Protein Defects—The three-dimensional structure of
the human factor XIII A-subunit zymogen dimer, experimentally deter-
mined by single crystal x-ray diffraction (5), was used as a template for
constructing a homology model of the human keratinocyte transglu-
taminase enzyme using the Biosym InsightII software package. Atomic
coordinates for the factor XIII structure were obtained by refining the
model against x-ray diffraction data from 10.0 to 2.65 Å resolution using
the program X-PLOR (49) to give a crystallographic R factor of 21.7%.
The final model exhibits good geometry (root mean square deviation
from ideality of 0.012 Å for bond lengths, 1.8° for bond angles, 25.6° for
torsion angles, and 1.5° for improper torsion angles); the average value
of the individually refined atomic temperature factors is 26.7 Å2. Re-
fined coordinates for the factor XIII structure have been deposited with
the Protein Data Bank (identifying code: 1ggt). Models of the keratino-
cyte transglutaminase mutant structures were generated by modifying
the homology model using the computer program O (50), and figures
were drawn with the program MOLSCRIPT (51).
RESULTS
Biochemical Characterization of the Patients—The mem-
brane TG activities in cultured cells from the probands ranged
from 2.2 (LI-20 III.1) to 175.4 pmol/h mg (LI-20 II.1), signifi-
cantly different from that in normal and heterozygotic (LI-8 I.1,
LI-22 III.3) individuals (Table I). Northern blots showed miss-
ing TGK mRNA in proband LI-8 II.2 and aberrant synthesis in
LI-22 IV.4 and LI-22 III.3, whereas probands from the other
two familes had normal sizes and levels of mRNA (Fig. 2). The
banding pattern obtained with the probes DH42 and 39 NC in
probands III.3 and IV.4 of LI-22 (Fig. 1) was very similar to the
one observed in the previously reported family LI-2, which had
a homozygous A to G change in the splice acceptor site of intron
5 (33). TGK protein levels in cytosolic and membrane fractions
were strongly decreased in all individuals with low TG activity
(Fig. 3a).
Sequence Analysis of Patients TGK Gene—The mutations
shown in Fig. 4 were detected by direct DNA sequencing of all
15 TGK exons in individuals with low TG activities. LI-8 II.2
had a homozygous C to T mutation at position 11354 in exon 3,
changing R127 to a stop codon. This mutation creates a new
DdeI site in exon 3 giving rise to a new band of 181 bp. DdeI
digestion of amplified exon 3 from the patient and his parents
showed that the patient was homozygous for the 181-bp band,
whereas the parents were heterozygous for the 181- and 207-bp
FIG. 1. Pedigrees of the LI families LI-8 (a), LI-11 (b), LI-20 (c),
and LI-22 (d). Genomic DNA samples were analyzed from the individ-
uals marked with underlined numbers. Cell cultures were established
from individuals marked with bold numbers.
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band (Fig. 4g). Patient LI-11 II.1 was a compound heterozygote
for two missense mutations. He carries a G to A change at
position 17110, changing Gly-473 to serine (Fig. 4a), and a C to
T change at 18479, changing Arg-687 to cysteine (Fig. 4b). In
family LI-20, patients III.1 and III.2 carry a heterozygous C to
G mutation at 14019 (S358R) inherited from the mother (Fig.
4c) and a heterozygous G to T change at 18509 in the splice
donor site of intron 13 inherited from the father (Fig. 4d).
Sequencing of 14 cDNA clones obtained by RT-PCR using total
RNA from patients LI-20 III.1 and III.2 (Fig. 1) with primers
DH5/DH7 (33) revealed that 10 clones contained a deletion of
54 nucleotides (18454 to 18509), whereas the remaining
clones had normal sequence. This implicates that the splicing
machinery uses GT at position 18454 as the new splice donor
site, which is consistent with the calculation of the consensus
values for putative splice acceptor sites (52, 53) 100 bp up- and
downstream of the mutated splice junction (data not shown).
This leads to an in-frame deletion of amino acids 679–696
(D679–696). Since the mother was affected by lamellar ichthy-
osis and showed low TG activity (Table I), all 15 of her exons
were sequenced. This revealed an additional heterozygous mu-
tation replacing a G nucleotide with C at position 14080 chang-
ing Val-379 into leucine (Fig. 4e). This mutation was not pres-
ent in her two children showing that the V379L and S358R
mutations are not on the same allele. Patient LI-22 IV.4 is a
compound heterozygote for an A to G (13366) change in the
splice acceptor site of intron 5 (data not shown) and a C to T
exchange at position 13434 (R315C) (Fig. 4f). The A to G
mutation at 13366 creates a new MspI site, allowing us to
follow the inheritance of the mutation in the LI-22 pedigree.
The mutant allele is present in the patient and was inherited
from his mother and maternal grandmother (data not shown).
The second mutation at 13434 destroys the single HaeIII site
in exon 6. The restriction enzyme analysis showed that only the
patient has this mutant band (data not shown). Whether this
mutation was inherited from the father or represents a new
mutation could not be tested since DNA from the father was not
available.
CpG dinucleotides have on the average a much higher rate of
mutations than other dinucleotides (54). In four of the pre-
sented 7 mutations (R127Stop, R315C, G473S, and R687C), C
nucleotides in CpG are mutated into a T either on the sense or
on the antisense DNA strand (G473S). Therefore, these sites
could constitute mutational hot spots.
Protein Modeling of the Mutants—The extensive conserva-
tion of amino acid residues of 42% between keratinocyte trans-
glutaminase and factor XIII A-subunit indicates that their
folding is conserved. Therefore, the factor XIII A-subunit crys-
tal structure served as a reliable scaffold to construct a homol-
ogy model of keratinocyte transglutaminase (Fig. 5) to better
understand the molecular basis for the decreased enzymatic
activity caused by the keratinocyte transglutaminase muta-
tions. Factor XIII A-subunit is composed of four domains,
which, from the N-terminal end, have been designated as
b-sandwich, central core domain, and b-barrels 1 and 2 (5). For
additional indications of the structural and functional impor-
tance of the mutation sites, a structure-guided alignment of 19
FIG. 2. Northern blot analysis of total RNA from cultured ke-
ratinocytes. Lane 1, LI-11 II.1; lane 2, LI-8 II.2; lane 3, LI-20 III.1;
lane 4, LI-20 III.2; lane 5, LI-22 III.3; lane 6, LI-22 IV.4; lane 7, LI-22
II.2; and lane 8, unaffected individual. The cDNA probes are from the
59- (DH42) and 39-ends (39 NC) of the TGK mRNA and the repetitive
region of involucrin (INV), see also under “Experimental Procedures.”
Involucrin is an epidermal differentiation marker that was included to
verify the differentiation status of keratinocyte cultures.
FIG. 3. a, TGK protein level is strongly decreased in LI patients.
Shown are immunoblots of cytosolic (lanes 2, 4, 6, 8, 10, 12, and 14) and
membrane (lanes 1, 3, 5, 7, 9, 11, 13, and 15) extracts from cultured
keratinocytes. Lane 1, unaffected individual; lanes 2 and 3, LI-8 II.2;
lanes 4 and 5, LI-11 II.1; lanes 6 and 7, LI-20 II.1; lanes 8 and 9, LI-20
III.1; lanes 10 and 11, LI-20 III.2; lanes 12 and 13, LI-22 III.3; lanes 14
and 15, LI-22 IV.4. Note abundant protein in LI-22 III.3 who is a
heterozygous carrier. b, transfected mutant TGK molecules are proteo-
lytically degraded. Immunoblot of cytosolic (lanes 2, 4, 6, 8, 10, 12, 14,
and 16) and membrane (lanes 1, 3, 5, 7, 9, 11, 13, and 15) extracts from
transfected TGK negative keratinocytes. Nontransfected (lanes 1 and
2), normal TGK (lanes 3 and 4), R687C (lanes 5 and 6), D679–696 (lanes
7 and 8), S42Y (lanes 9 and 10), R142C (lanes 11 and 12), S42Y/R142C
(lanes 13 and 14), R323Q (lanes 15 and 16). Molecular sizes (kilodal-
tons) are indicated on the left.
TABLE I
TG activity in keratinocytes from LI families and normal individuals
Family Proband
Activitya
Cytosol Membrane Mutationsb
LI-8 I.1 248.8 6 46.0 2944.0 6 711.0
LI-8 II.2 5.8 6 1.1 13.9 6 1.8 R127PTC/R127PTC
LI-11 II.1 10.9 6 2.2 24.3 6 7.3 G473S/R687C
LI-20 II.1 76.3 6 5.5 175.4 6 44.0 S358R/V379L
LI-20 III.1 2.0 6 1.1 2.2 6 0.3 S358R/D679–696
LI-20 III.2 5.6 6 2.1 4.0 6 1.9 S358R/D679–696
LI-22 II.2 497.8 6 52.0 6194.0 6 210.0
LI-22 III.3 205.1 6 81.0 2600.0 6 414.0
LI-22 IV.4 4.0 6 2.4 52.0 6 4.9 R315C/SA intron 5
Normalc 351.9 6 125.7 4200.0 6 200.0
a Activity is presented as pmol/h mg of putrescine incorporated. Results are given as mean 6 S.E. from at least two cell passages in duplicate.
b SA means the splice acceptor site of the intron; PTC means premature stop codon.
c Results are derived from 7 unaffected individuals and are presented as mean 6 S.E.
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known transglutaminase sequences was additionally used
(data not shown).
R315C—Residue Arg-315, in the catalytic core domain, is
located in a surface loop between two helices (Fig. 5). The
arginine side chain is buried in the structure and forms a salt
bridge with Asp-306 as well as a hydrogen bond to the main
chain carbonyl group of Met-310 (Fig. 6). These bonds serve to
stabilize the conformation of this surface loop. The Arg-315–
Asp-306 salt bridge is conserved in a total of 13 of the TG
sequences including factor XIII A-subunit and TGK; in one of
the other sequences, the equivalent arginine residue interacts
with a glutamic acid side chain, and in the remaining mole-
cules, the size of this loop is altered by either amino acid
insertions or deletions. The equivalent arginine in factor XIII
A-subunit is the site of the deficiency mutation R252I (55),
underlining the structural importance of this residue. The TGK
FIG. 6. Close-up view of the modelled R315C mutation site. In
the factor XIII crystal structure, the side chain of this arginine residue
forms a salt bridge with an aspartic acid residue, and both amino acids
are conserved in factor XIII and the keratinocyte transglutaminase
sequences. Arg-315 also forms hydrogen bonds with the main chain
carbonyl of Met-310, which is also conserved. All three residues are
located in a surface loop between two helices in the catalytic core
domain. Replacement of the large Arg-315 side chain with that of the
smaller cysteine residue results in removal of all the wild-type hydro-
gen-bonding interactions and creates a gap in the molecule.
FIG. 4. Sequencing (a-e) and agarose (g) gels demonstrate
novel mutations in family LI-11 (a and b), LI-20 (c-e), LI-22 (f),
and LI-8 (g). a, G to A change in exon 10, resulting in a G473S
substitution; b, C to T in exon 13, which alters Arg-687 to cysteine; c, C
to G change in exon 7, altering Ser-358 to arginine; d, G to T change in
intron 13, destroying its splice donor site and leading to deletion of
amino acids 679 to 696; e, an additional mutation was found in the DNA
of the mother, replacing a G with a C nucleotide in exon 7, changing
Val-379 to leucine; f, C to T change in exon 6, changing Arg-315 to
cysteine; g, homozygous C to T mutation in exon 3, changing R127 to a
premature stop codon. This mutation creates a new DdeI site (giving
rise to a new band of 181 bp), which was used for family analysis. g, lane
1, mother I.1; lane 2, patient II.2; lane 3, father I.2; lane 4, normal
control; and lane 5, molecular weight marker.
FIG. 5. Most of the mutations are located in the central core
domain of TGK. Stereo view showing the location of the six keratino-
cyte transglutaminase mutation sites in the transglutaminase fold con-
structed based on the three-dimensional structure of the factor XIII
A-subunit (5). Since the N-terminal activation peptide of factor XIII is
not conserved in keratinocyte transglutaminase, it has been omitted
from the figure for clarity. The active site is marked by a large asterisk,
and the three regions of amino acid deletions in the keratinocyte trans-
glutaminase relative to factor XIII are shown as thick dark lines. The
alpha carbon atoms of the six mutation sites (315, 358, 379, 473, 687,
and D679–696) are shown as large labeled spheres.
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R315C mutation has three effects. First, the described bonds
formed by the arginine side chain are removed, rendering the
surface loop more mobile and susceptible to proteolytic cleav-
age. Second, the introduction of the smaller cysteine side chain
leaves a void in the molecule that would destabilize the struc-
ture; a possible consequence is interference with proper folding
and the generation of an altered structure. Third, the introduc-
tion of an additional cysteine residue can interfere with proper
folding by allowing the formation of an unwanted disulfide
bond. Thus, the most likely result of the R315C mutation is the
altered conformation of the surface loop yielding a modified
structure that is less stable and more susceptible to proteolytic
cleavage.
S358R—The Ser-358 residue is absolutely conserved in all
19 TG sequences, which suggests structural and/or functional
importance. This residue is located in the catalytic core domain
(Fig. 5), and its side chain group is buried in the molecule. The
Ser-358 side chain hydrogen bonds to the side chains of resi-
dues Thr-386 and Trp-288 and to the main-chain carbonyl of
Gly-382 (Fig. 7). Since Thr-386 and Trp-288 are also absolutely
conserved in the 19 TG and the Gly-382 main-chain torsion
angles can easily accommodate other residues (this position is
occupied by either a glycine or an alanine in the TG sequences),
all three hydrogen bonds involving the Ser-358 are expected to
be conserved among the TG structures and are likely to be
structurally important. The S358R mutation is expected to
have three important consequences. First, the mutation re-
moves the three conserved hydrogen bonds that are likely to be
critical for protein folding and stability. Second, to accommo-
date the much larger arginine side chain, the conformation of
the protein at the mutation site must be dramatically altered.
Finally, the arginine mutation introduces a buried positive
charge in the protein, which will further interfere with proper
folding of the protein. The result of the S358R mutation is
predicted to be a dramatic misfolding of the catalytic core
domain.
V379L—Residue Val-379, which is absolutely conserved, is
located 2 positions C-terminal to the catalytic Cys-377 in the
FIG. 7. Stereo view of the modelled
S358R mutation site. The Ser-358 resi-
due (dark gray) is absolutely conserved in
all transglutaminase sequences. Its side
chain group is buried in the catalytic core
domain and involved in a number of
hydrogen-bonding interactions (dashed
lines) with the side chain groups of con-
served residues Trp-288 and Thr-386 and
to the main chain carbonyl of Gly-382.
Replacement of Ser-358 with an arginine
residue (white) leads to the disruption of
hydrogen-bonding interactions and the
larger arginine side chain introduces a
number of short contacts that must be
relieved by a conformational rearrange-
ment of the protein. The likely result is a
dramatic misfolding of the catalytic core
domain.
FIG. 8. Stereo view of the modelled
V379L mutation site. The Val-379 resi-
due is located in the active site helix
(shown as a coil), two residues C-terminal
to the catalytic Cys-377 residue. The con-
served Val-379 side chain, shown in dark
gray ball and stick, is buried in a closely
packed hydrophobic pocket in the cata-
lytic core domain. The V379L mutation
(white ball and stick) introduces a larger
side chain, resulting in a number of steri-
cally unfavorable short contacts that are
relieved by distortion of the protein fold.
This in turn leads to a shift of the cata-
lytic Cys-377 residue affecting the enzy-
matic activity of TGK.
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active site helix that contains a number of conserved amino
acids (Fig. 8). The Val-379 side chain is buried in a tightly
packed hydrophobic environment formed by predominantly
conserved residues and that cannot accommodate the larger
leucine side chain of the V379L mutation without distortion of
the local conformation of the protein. As a result of the ordi-
narily conservative V379L mutation, the position and orienta-
tion of the catalytic Cys-377 are likely to be altered, and the
catalytic activity of the enzyme compromised.
G473S—Residue Gly-473 is conserved in all TG sequences
except for the two band 4.2 proteins. This glycine residue is
found on the surface of the catalytic core domain (Fig. 5) and,
along with Pro-474 (conserved in all but the band 4.2 se-
quences), forms the only cis-peptide bond in the factor XIII
A-subunit. The main chain atoms of Gly-473 form hydrogen
bonds with the side chains of two residues: Arg-323, which is
absolutely conserved among the 19 sequences, and Asp-490,
which is conserved in all but the two band 4.2 proteins (Fig. 9).
The pattern of conservation of the Gly-473–Pro-474 pair and
residues Arg-323 and Asp-490 in all 17 enzymatic TG se-
quences suggests that the conformation of the protein fold in
this region, as determined by the cis-peptide geometry and the
conserved hydrogen-bonding interactions, is crucial for cata-
lytic activity. Consistent with this interpretation are the obser-
vations that Arg-323 is the site of a previously identified la-
mellar ichthyosis missense mutation as well as of the factor
FIG. 9. Stereo view of the modelled
G473S mutation site. Residues Gly-473
and Pro-474 are amino acids conserved
among all the enzymatic transglutami-
nase sequences; in the factor XIII A-sub-
unit structure, the Gly-473–Pro-474 pep-
tide bond is the only one observed to be in
the cis conformation. Gly-473 atoms (dark
gray) participate in hydrogen-bonding in-
teractions with the side chains of the
highly conserved Arg-323 and Asp-490
residues. The main chain conformation of
Gly-473 is unsuitable for any other amino
acid with its larger side chain; substitu-
tion of Gly-473 with a serine residue
(white ball and stick) would interfere with
proper folding of the protein.
FIG. 10. Stereo view of the R687C
mutation site. The Arg-687 residue
(dark gray) is buried at the interface be-
tween the barrel 1 and catalytic core do-
mains and is variable among the trans-
glutaminase sequences. The side chain of
this arginine residue is not predicted to be
involved in any interactions critical dur-
ing the protein folding process. Substitu-
tion of the large buried Arg-687 side chain
with the much smaller cysteine residue is
likely to interfere with the domain-
domain interface. The result is a folded
protein with a modified quaternary struc-
ture that has altered substrate binding
and specificity or that is less stable or
more easily degraded by proteases.
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XIII A-subunit deficiency mutant R260C (33, 56). The G473S
mutation will lead to a misfolded structure that is conforma-
tionally distorted since the glycine main-chain torsion angles
cannot accommodate any other amino acid with its larger side
chain; the serine side chain would introduce sterically unfavor-
able short contacts with main-chain atoms. The serine substi-
tution will interfere with the folding process and yield an
altered structure that is less stable or more susceptible to
proteolytic cleavage.
R687C—The Arg-687 residue is buried at the interface be-
tween the C-terminal b-barrels and the catalytic core domains
(Figs. 5 and 10) and is found only in the keratinocyte se-
quences. The consequence of the R687C mutation is not as
evident as for the other four missense mutations. The variabil-
ity of this residue among the transglutaminases indicates that
this residue is not likely to be important during the protein
folding process. Although there are few conserved residues at
the barrel-core domain interface, the barrel domains are ex-
pected to be packed well against the catalytic core domains in
all transglutaminase structures. Substitution of the large, pos-
itively-charged buried Arg-687 side chain with the much
smaller cysteine residue is likely to interfere with the interdo-
main interface, and to yield a modified quaternary structure.
The result is a globally altered molecule that is less stable or
more easily degraded by proteases (see Fig. 3a, lanes 4 and 5
and Fig. 3b, lanes 5 and 6) but also might have altered sub-
strate binding and specificity.
D679–696—The 18 residue deletion in the region corre-
sponding to residues 618–635 in factor XIII A-subunit forms
one long strand that starts in barrel 1 and continues to barrel
2 (Fig. 5). The first part of the peptide forms most of a b-strand
in barrel 1 at its interface with the core domain. The second
part of the peptide forms half of a b-strand in barrel 2. Deletion
of these 18 residues has dramatic structural effects. In a worst-
case scenario, the C-terminal portion of the protein is unable to
fold into a globular structure, and the entire molecule is un-
stable and degraded as shown by Western blot analysis (Fig.
3a, lanes 8–11 and Fig. 3b, lanes 7 and 8). In a best-case
scenario, the C-terminal portion (barrels 1 and 2) folds into an
altered globular structure, and the modified protein is stable.
However, in this case, the new C-terminal domain will not only
have an altered structure but will also not be packed against
the catalytic core in the same manner, thus any putative func-
tion served by the barrel domains (substrate binding and spec-
ificity, specificity of enzyme cleavage, and activation) will be
lost.
Transient Expression of the Mutants R687C and D679–
696—Since the mutations R687C and D679–696 do not con-
cern highly conserved residues, it was less evident if they
would influence TG activity. Therefore, these mutant cDNAs
were transiently expressed by cotransfections with a b-galac-
tosidase expression plasmid into TGK negative keratinocytes
derived from a LI patient. The mutation R687C reduces mem-
brane TG activity to about 5% of the normal level (Table II). An
even stronger reduction was observed for the D679–696 pro-
tein molecule (Table II). The three mutations S42Y, R142C,
and R323Q were reported earlier in a LI family (33) and were
included in Table II to demonstrate the ability of this transient
expression assay to detect deleterious mutations. The data
show also that the S42Y change, located close to the membrane
attachment site of the molecule, is not a disease-causing mu-
tation but does lead to increased cytosolic accumulation of TGK
as previously postulated (33). Furthermore, Western blot anal-
ysis of cell extracts from transfected cells demonstrated an
excellent correlation between the levels of TGK protein and TG
activity (Fig. 3b). These results prove that the mutations
R687C and D679–696 are indeed disease-causing mutations.
DISCUSSION
In this study, we have investigated structure-function rela-
tionships in TGK by analyzing mutants found in LI patients.
Using biochemical techniques and direct sequencing, we have
identified 7 novel mutations in the gene of keratinocyte trans-
glutaminase. Five of the mutations were one-nucleotide
changes resulting in single amino acid alterations (R315C,
S358R, V379L, G473S, R687C), one point mutation led to a
premature termination codon (R127Stop), and one mutation
affected the splice donor site of intron 13 leading to an in-frame
deletion of 18 amino acids (D679–696). One mutation changing
the splice acceptor site of intron 5 has already been reported in
a family (33) and, in fact, the aberrant RNA banding pattern
(Fig. 2) gave an important clue to identify the mutation. In the
case of the nonsense mutation, R127Stop, the steady-state
transcript level was very low (Fig. 2). The association of stop
mutations with reduced mRNA levels has been reported in
other genes and is due to low efficiency in transcript processing
and/or mRNA transport from the nucleoplasma (57). In con-
trast, the mRNA levels of all missense mutations are expressed
in comparable amounts as in normal probands, in accordance
with observations for other genes.
The three-dimensional structure of TGK is currently not
known. Thus, the structural effects of the reported missense
and deletion mutations were analyzed using the factor XIII
A-subunit structure (Fig. 5) (5). The central core domain, con-
taining the active site cysteine, displays the highest homology
between factor XIII A-subunit and TGK, whereas the other
domains are less conserved. Sequence alignment of the two
proteins shows that most of the mutations (R315C, S358R,
V379L, G473S) are located in a region corresponding to the
central core domain. Amino acid changes can decrease enzyme
activity either by interfering directly with the catalytic mech-
anism, by introducing gross structural alteration, or by block-
ing the binding of essential cofactors. With the exception of
V379L, these mutations do not concern residues close to the
catalytic site. Rather, these mutations are predicted to inter-
fere with proper formation of hydrogen bonds and salt bridges
and introduce spatial constraints due to differing side chain
sizes that alter protein structure. These mutants are unstable
and/or more susceptible to proteolytic degradation (58, 59). Our
predictions are supported by the results of immunoblotting
experiments showing strongly decreased levels of TGK proteins
in cultured cells from these patients. Thus, these missense
mutations lead to protein instability and premature degrada-
tion but do not interfere directly with the catalytic mechanism.
Congenital factor XIII deficiency, a rare bleeding disorder, can
be caused by mutations in the gene for the factor XIII A-sub-
unit. Arg-252, which corresponds to Arg-315 in TGK, was al-
tered to Ile in a patient affected by this disorder (55). In agree-
ment with our results, low TG activity and protein level were
TABLE II
Relative TG activity of transfected mutant TGK cDNA
Mutant Cytosol Membrane
Wild-type 100.0 100.0
R687C 7.4 6 1.9 5.4 6 1.7
D679–696 2.3 6 1.0 0.1 6 0.02
S42Y 159.2 6 14.3 93.6 6 3.2
R142C 4.7 6 1.2 0.5 6 0.1
S42Y/R142C 6.2 6 4.9 0.2 6 0.02
R323Q 18.3 6 0.4 2.2 6 0.5
Relative TG activities have been normalized for transfection effi-
ciency by cotransfection with a b-galactosidase expression plasmid (see
“Experimental Procedures”) and are presented as percent of the activity
of the wild-type molecule set as 100%. Results are presented as mean 6
S.E. from two independent experiments measured in duplicate.
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reported in this patient. The qualitative agreement between
these results underlines that the factor XIII A-subunit subunit
can serve as valuable model for predicting the structural and
functional effects of TGK mutants.
Val-379 is located two amino acids C-terminal of the active
site Cys-377. Although Val-379 does not belong to the catalytic
triad (Cys, His, Asp), it is located in the same a-helix as Cys-
377. Replacing valine with leucine changes the conformation of
this a-helix and therefore the spatial position of Cys-377 rela-
tive Asp and His due to the additional space occupied by the
larger leucine side chain in a tightly packed region (Fig. 8).
This structural change, ordinarily conservative, in family LI-20
is drastic enough to cause premature proteolytic degradation
(Fig. 3a). Site-directed mutagenesis of Val-316 in factor XIII
A-subunit (homolog to Val-379 in TGK) to Ala reduced activity
to 34% of the unmutated enzyme (60). The difference in reduc-
tion between the enzymatic activities of the two mutants is
most likely due to the different sizes of the side chain (Ala
versus Leu) replacing valine. Furthermore, we found in another
LI patient a homozygotic V379M substitution.2 These results
indicate that the TG activity is very sensitive to changes in the
valine two amino acids C-terminal of the active site cysteine.
The mutations R687C and D679–696 are located at the C
terminus, which corresponds to the b-barrel domains of factor
XIII A-subunit. These domains are not highly conserved; Arg-
687 is found only in the keratinocyte sequences, and 11 of 18
amino acids from the deletion mutant are different between
TGK and factor XIII A-subunit. Since this precluded analysis of
these mutations using the factor XIII A-subunit model, the
corresponding mutant cDNAs were expressed in TGK negative
keratinocytes. This showed that both mutations strongly de-
creased the enzymatic activities and led to premature degra-
dation of the enzyme in a manner comparable with mutations
in the highly conserved central core or b-sandwich domains
(Fig. 3b and Table II). Three mutations, two misssense and a
premature stop codon, in the b-barrel 2 of factor XIII A subunit
were also reported to diminish enzyme activity and protein
levels (61–63). Previous experiments in which deletion con-
structs of TGK were expressed in bacteria showed that removal
of amino acids 675–816 resulted in a substantially reduced
specific activity (22). Interestingly, further deletion of 100
amino acids restored the activity nearly to the level of the
full-length protein (22). In a series of experiments, it was dem-
onstrated that TGK exists in keratinocytes as complexes of
polypeptides derived from the full-length enzyme by proteolysis
(18, 19). Depending on the differentiation status and cellular
localization, enzymatically active 67 kDa, 67/33 kDa, and 10/
67/33 kDa complexes were found in which the 67 kDa, the 33
kDa, and 10 kDa molecules correspond to the b-sandwich plus
central core domains, C-terminal b-barrel domains, and the
first 92 amino acids of the N terminus, respectively. Further-
more, elimination of the two b-barrels in bacterial-expressed
factor XIII A-chain molecules only slightly diminished enzy-
matic activity, and the shortened molecules conserved the abil-
ity to be activated by thrombin and calcium and the binding
and cross-linking of fibrin (64). Interestingly, C-terminal dele-
tions of human tissue transglutaminase were reported to en-
hance its intrinsic GTP/ATPase activity concomittant with a
lowering in TG activity (65). In summary, these data indicate
that the b-barrel domains are not absolutely required for trans-
glutaminase activity, but they augment activity possibly due to
better substrate interaction and enzyme activation. However,
our results and those from others suggest that mutations
within the b-barrel domains have in most cases a profound
influence on the whole molecule because they promote prema-
ture degradation and/or interfere with the proper functioning
of the active site. Additional structural investigations are
needed to elucidate further the function of the C-terminal do-
mains of transglutaminases.
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